We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-4.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.49B
AUM Growth
-$101M
Cap. Flow
+$10.3M
Cap. Flow %
0.69%
Top 10 Hldgs %
30.22%
Holding
143
New
5
Increased
56
Reduced
18
Closed
10

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$24.6M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$24.2M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$11.2M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.9M
5
MRK icon
Merck
MRK
+$9.97M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.8M
2
HCA icon
HCA Healthcare
HCA
+$32.5M
3
MCK icon
McKesson
MCK
+$13.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.83M
5
GI
EndoChoice Holdings, Inc.
GI
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 81.35%
2 Financials 4.56%
3 Industrials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEN icon
26
Penumbra
PEN
$12.8B
$18.9M 1.26%
295,500
+29,000
+11% +$1.94M
INCY icon
27
Incyte
INCY
$24.4B
$16.9M 1.13%
169,000
+12,500
+8% +$1.22M
PRAH
28
DELISTED
PRA Health Sciences, Inc.
PRAH
$16.5M 1.11%
300,000
+47,000
+19% +$2.58M
NBIX icon
29
Neurocrine Biosciences
NBIX
$16.6B
$15.9M 1.06%
410,000
– –
AMRN
30
Amarin Corp
AMRN
$303M
$15.4M 1.03%
249,575
+1,788
+0.7% +$114K
WMGI
31
DELISTED
Wright Medical Group Inc
WMGI
$15.3M 1.03%
667,000
+54,000
+9% +$1.26M
PRTA icon
32
Prothena Corp
PRTA
$450M
$15.2M 1.02%
309,500
+1,500
+0.5% +$82.8K
AMGN icon
33
Amgen
AMGN
$222B
$14.1M 0.94%
96,500
+2,500
+3% +$376K
CHRS icon
34
Coherus Oncology
CHRS
$196M
$13.6M 0.91%
484,500
+17,000
+4% +$476K
JAZZ icon
35
Jazz Pharmaceuticals
JAZZ
$16.7B
$13.5M 0.9%
123,700
+16,700
+16% +$1.86M
LKFT
36
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$13.5M 0.9%
210,000
– –
WTW icon
37
Willis Towers Watson
WTW
$32B
$13.5M 0.9%
110,000
+51,500
+88% +$6.42M
BIIB icon
38
Biogen
BIIB
$30.7B
$13.3M 0.89%
47,000
-11,000
-19% -$3.26M
WBA
39
DELISTED
Walgreens Boots Alliance
WBA
$13.3M 0.89%
161,000
– –
RARX
40
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$12.5M 0.84%
+826,000
New +$11.2M
DHR icon
41
Danaher
DHR
$144B
$12.5M 0.83%
180,480
– –
PTHN
42
DELISTED
Patheon N.V.
PTHN
$11.5M 0.77%
400,000
– –
EW icon
43
Edwards Lifesciences
EW
$51.7B
$11.3M 0.76%
361,500
+51,750
+17% +$1.68M
RARE icon
44
Ultragenyx Pharmaceutical
RARE
$2.55B
$11.2M 0.75%
159,750
+12,750
+9% +$905K
DERM
45
DELISTED
Dermira, Inc.
DERM
$11M 0.74%
362,600
+7,600
+2% +$245K
EHC icon
46
Encompass Health
EHC
$12.4B
$10.9M 0.73%
333,105
– –
HOLX
47
DELISTED
Hologic
HOLX
$10.6M 0.71%
265,000
+12,500
+5% +$482K
BMRN icon
48
BioMarin Pharmaceuticals
BMRN
$12.4B
$10.4M 0.69%
125,000
– –
TXMD icon
49
TherapeuticsMD
TXMD
$24M
$9.92M 0.66%
34,400
-1,600
-4% -$496K
TVTX icon
50
Travere Therapeutics
TVTX
$5.78B
$9.88M 0.66%
522,000
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Rock Springs Capital Management held 143 positions worth $1.49B, down 6.3% from $1.6B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2016 filing shows 5 new, 56 increased, 18 reduced and 10 closed positions. Its largest new stake was UnitedHealth: 165,000 shares worth $26.4M. The largest sale was Pfizer, an estimated $35.8M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2016 buy was UnitedHealth: 165,000 shares worth $26.4M.
  • Rock Springs Capital Management added most to Alexion Pharmaceuticals in Q4 2016, an estimated $24.2M increase.
  • Rock Springs Capital Management's biggest Q4 2016 reduction was Gilead Sciences, cutting an estimated $5.02M.
  • Rock Springs Capital Management fully exited Pfizer in Q4 2016, selling an estimated $35.8M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $1.49B portfolio in Q4 2016.
  • Rock Springs Capital Management opened 5 new positions and closed 10 in Q4 2016.
  • Rock Springs Capital Management's portfolio value fell 6.3% quarter-over-quarter to $1.49B.

Based on Rock Springs Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.